UK Biotech given green light to begin stem cell therapy clinical trial for heart failure

UK biotech, Celixir, has received a green light to start a phase IIb trial of HeartCel, its stem cell-based therapy for heart failure, that could potentially support approval. Heartcel is a preparation of off-the-shelf immunomodulatory progenitor (iMP) cells that are injected around cardiac scar tissue during coronary artery bypass graft (CABG) surgery in the hope

Continue Reading